Skip to main content
RGNX logo

RGNX · REGENXBIO Inc.

Track RGNX — free
$7.16 -0.02 (-0.28%) At close · Nov 20
Market Cap
$473.44M
Shares
66.12M
Volume · Nov 20 1.06M Avg daily vol (3M) 1.38M

Price & Indicators

 

Key stats

Close
$7.16
Fri 20 Nov
Open
$7.00
Fri 20 Nov
Average volume, 30 days
1.3M
shares a session
Short interest
10.2M
15.4% of shares · 8.3 days to cover
Day range
$6.86$7.30
Open $7.00 Close $7.16
52-week closing range
$5.65$15.98
Close $7.16 55.2% under the high
Short volume, last session
55%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 5
Price history
Jan 2020 to Nov 2026

Up next

Mar 4, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 5
Earnings call
Suravec data and RGX202 filing loom with $251 million cash

Regenexx Bio said Suravec wet AMD pivotal data are expected this quarter, RGX202’s full BLA filing is planned for the first quarter of 2027, and cash, cash equivalents and marketable securities totaled $251 million at September 30, 2026.

5 source passages
Earlier this morning, Regenexx Bio released financial and operating results for the third quarter ended September 30, 2026. The SURAVEC pivotal top-line data expected this quarter could reshape the treatment paradigm for WET-AMD. Turning to RGX202, we continue to make meaningful progress towards bringing our potential best-in-class gene therapy for Duchenne to patients in the U.S. and beyond. Preparations are well underway to submit the BLA under the Accelerated Approval Pathway in the first quarter of 2027, supporting potential approval in the U.S. in the second half of 2027. Regenix file ended the third quarter of 2026 with cash, cash equivalent, and marketable securities of $251 million compared to $241 million as of December 31st, 2025. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Pivotal RGX-202 success contrasts with RGX-121 hold

REGENXBIO reported positive pivotal RGX-202 results and plans a BLA submission in the first quarter of 2027, while RGX-121 remains on clinical hold. The wet AMD pivotal program completed enrollment, with topline data expected in the fourth quarter of 2026.

Revenue $9.16M ▼ 69.2% Net loss $40.74M Diluted EPS -$0.62
Read from the MD&A section
5 source passages
In May 2026, we announced positive topline results from the pivotal Phase III AFFINITY DUCHENNE trial of RGX-202 Given the positive topline pivotal data, continued favorable safety profile, and statistically significant correlation between microdystrophin and functional improvement, we expect to hold a pre-Biologics License Application (BLA) meeting with the FDA in the fourth quarter of 2026 and submit a BLA in the first quarter of 2027 under the accelerated approval pathway, supporting potential FDA approval in the second half of 2027. In August 2026, we announced that the FDA placed a clinical hold on RGX-121 following the discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE study. Enrollment in the ATMOSPHERE and ASCENT pivotal trials for the treatment of patients with wet AMD using subretinal delivery was completed in October 2025. Topline data from these trials are expected to be announced in the fourth quarter of 2026 in partnership with AbbVie Open the document at this passage
Nov 5
Current report 8-K
RGX-202 BLA submission on track for Q1 2027

REGENXBIO remains on track to submit the RGX-202 BLA in Q1 2027, while reporting $251.0 million in cash, cash equivalents and marketable securities and a $40.7 million net loss for the third quarter ended September 30, 2026.

Financial results
4 source passages
Neuromuscular Disease: RGX-202 is a potential best-in-class gene therapy for Duchenne muscular dystrophy (Duchenne). The Company expects to have a pre-Biologics License Application (BLA) meeting with the FDA in Q4 2026 and is on track to submit a BLA in Q1 2027 under the accelerated approval pathway, supporting potential approval in 2H 2027. Cash, cash equivalents and marketable securities were $251.0 million as of September 30, 2026, compared to $240.9 million as of December 31, 2025. Net loss was $40.7 million, or $0.62 basic and diluted net loss per share, for the three months ended September 30, 2026, compared to a net loss of $61.9 million, or $1.20 basic and diluted net loss per share, for the three months ended September 30, 2025. Open the document at this passage
Oct 16
Current report 8-K Events of Oct 14
Kenneth T. Mills resigns from board; George Migausky named Chairman

Kenneth T. Mills resigned from the board effective October 21, 2026, to focus on his new role as chief executive officer of another company. The board appointed George Migausky as Chairman, and Daniel Tassé stepped down as Lead Independent Director but remains a board member.

Director or officer change, or executive pay
3 source passages
On October 14, 2026, Kenneth T. Mills resigned from the board of directors (the “Board”) of REGENXBIO Inc. (the “Company”) effective October 21, 2026. In connection with Mr. Mills’ departure, the Board appointed George Migausky as Chairman of the Board (“Chairman”). In accordance with the Company’s Corporate Governance Guidelines, Daniel Tassé has stepped down from his position as Lead Independent Director, as the new Chairman is an independent director, but will remain a member of the Board. Open the document at this passage
Sep 23
Current report 8-K
Entered into a material agreement

On September 23, 2026, REGENXBIO Inc. entered a settlement with Sarepta that requires a $39.0 million payment to REGENXBIO within 10 days of the effective date and terminates all ongoing patent litigation over ELEVIDYS-related patents.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$153.91M
Trailing 12 months
Net income (TTM)
−$175.23M
Trailing 12 months
Revenue growth YoY
-69.2%
Year over year
Operating margin
-95.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-32.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$250.98M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+26.3%
Year over year · more shares
Price change (1Y)
-34.1%
Trailing year
Short interest
15.4%
Latest settlement · 8.3 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Sura-vec is approaching a Q4 2026 wet AMD data readout, RGX-202 remains on track for a Q1 2027 BLA submission, and available cash is expected to fund operations into late Q4 2027. The main negatives are lower revenue following the ZOLGENSMA patent expiration, higher R&D expenses, cash used in operating activities, and an FDA clinical hold on RGX-121.

Bullish
  • + Sura-vec wet AMD topline data are expected in Q4 2026, with global regulatory submissions expected in 2027.
  • + The RGX-202 BLA submission is on track for Q1 2027.
  • + Pivotal results showed robust microdistrophin expression, encouraging functional improvement, and a favorable safety profile.
  • + At three years, 60% of patients in the ALTITUDE trial improved by at least two steps on the diabetic retinopathy severity scale without additional treatment.
  • + Cash, cash equivalents, and marketable securities plus the October settlement proceeds are expected to fund operations into late Q4 2027.
  • + The $39.0 million Sarepta settlement payment was received in October 2026, and REGENXBIO recorded a $38.0 million third-quarter gain.
Bearish
  • − Third-quarter revenue fell to $9.2 million from $29.7 million a year earlier.
  • − ZOLGENSMA royalty revenue decreased by $21.2 million, primarily because licensed U.S. patents expired in January 2026.
  • − Third-quarter R&D expenses increased to $61.0 million from $56.1 million.
  • − The FDA placed RGX-121 on clinical hold after asymptomatic spine MRI findings were discovered in five CAMPSIITE participants.
  • − Cash used to fund operating activities during the nine months ended September 30, 2026 partially offset the year-to-date increase in cash and marketable securities.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −19%
below
Price vs 50-day avg −5%
below
RSI (14) 45
neutral
MACD trend Negative
52-week position 15%
near low
Momentum
relative strength
Strong
1-month return +7%
trailing
6-month return +10%
trailing
YTD return −50%
this year
Relative strength +19%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $8 › 200d $9 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +33 funds added
Insider flow Accumulating
Net +$949.4K over 90 days · 0% sells
Short interest Rising
15.40% of shares out · ▲ +1.4% MoM · 8.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
174 holders — mid 3-yr range
Squeeze score 66
elevated · 0–100
Fundamentals
Strong
Revenue growth +126%
Y/Y
EPS growth +18%
Y/Y
Free cash flow $-126.4M
Quant / Vol
risk profile
Very High
Volatility 93%
annualized · 1-yr
Max drawdown −65%
past year
ATR 7.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 5, 2026
Goal of at least 50 percent reduction in treatment burden · not stated at least 50%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−19% Bearish
Price vs 50-day avg
−5% Neutral
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
15% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $8 › 200d $9 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +33 funds added
Insider flow Accumulating
Net +$949.4K over 90 days · 0% sells
Short interest Rising
15.40% of shares out · ▲ +1.4% MoM · 8.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
174 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6 Now $7 · 15% Range high $16
vs 200-day avg -19% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and marketable securities $251M as of September 30, 2026 —
Interest income from licensing $10K Three Months Ended June 30, 2026 filing —
License and royalty revenue under AbbVie Collaboration Agreement $100M Three Months Ended June 30, 2026 filing —
Net cost reimbursement to (from) AbbVie included in General and administrative expense $1.23M Three Months Ended June 30, 2026 filing —
Net cost reimbursement to (from) AbbVie included in Research and development expense -$12.05M Three Months Ended June 30, 2026 filing —
Total net cost reimbursement to (from) AbbVie -$10.82M Three Months Ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RGNX
REGENXBIO Inc.
this stock
$473.44M -50.3% +126.5% — 15.4%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
174
% held
82.1%
Net QoQ
+12.1M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
192
View
Short & Settlement
Short Interest Rising
Shares short
10.2M
Days to cover
8.3d
Change
+136.0K sh
View
Short Volume
Short vol %
55%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
54
Value
$419
As of
Oct 6, 2026
View
Off-Exchange
Off-exchange %
41.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$949.4K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$170.4M
Net income (FY)
$-193.9M
EPS diluted
$-3.76
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 5, 2026
This year
31

REGENXBIO remains on track to submit the RGX-202 BLA in Q1 2027, while reporting $251.0 million in cash, cash equivalents and marketable securities and a $40.7 million net loss for the third quarter ended September 30, 2026.

View
Proposed Sales
Value
$517.6K
Shares
43.2K
Filed
Jul 1, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 11, 2026
View
Investor Relations
Latest news
REGENXBIO REPORTS THIRD QUARTER 2…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
RGNX -6.3% +7.2% +9.8% -0.6% -50.3%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +2.3% +16.4% +19.0% +8.2% -51.4%
Key facts CIK 1590877 CUSIP 75901B107 13F (30d) 173 filings 157 filers Visit website Investor relations